Medical - Devices
Compare Stocks
2 / 10Stock Comparison
CERS vs NTRA
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
CERS vs NTRA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Devices | Medical - Diagnostics & Research |
| Market Cap | $519M | $29.58B |
| Revenue (TTM) | $217M | $2.12B |
| Net Income (TTM) | $-10M | $-309M |
| Gross Margin | 53.0% | 63.7% |
| Operating Margin | -8.2% | -16.6% |
| Total Debt | $97M | $187M |
| Cash & Equiv. | $20M | $946M |
CERS vs NTRA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cerus Corporation (CERS) | 100 | 41.6 | -58.4% |
| Natera, Inc. (NTRA) | 100 | 490.5 | +390.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CERS vs NTRA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CERS carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- -4.4% margin vs NTRA's -14.6%
- +107.2% vs NTRA's +38.3%
NTRA is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.26
- Rev growth 56.7%, EPS growth 59.5%, 3Y rev CAGR 39.5%
- 21.5% 10Y total return vs CERS's -53.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 56.7% revenue growth vs CERS's 14.3% | |
| Value | Better valuation composite | |
| Quality / Margins | -4.4% margin vs NTRA's -14.6% | |
| Stability / Safety | Beta 1.26 vs CERS's 2.13, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +107.2% vs NTRA's +38.3% | |
| Efficiency (ROA) | -4.4% ROA vs NTRA's -17.0%, ROIC -19.7% vs -33.3% |
CERS vs NTRA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CERS vs NTRA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — CERS and NTRA each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NTRA is the larger business by revenue, generating $2.1B annually — 9.8x CERS's $217M. CERS is the more profitable business, keeping -4.4% of every revenue dollar as net income compared to NTRA's -14.6%. On growth, NTRA holds the edge at +34.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $217M | $2.1B |
| EBITDAEarnings before interest/tax | -$16M | -$315M |
| Net IncomeAfter-tax profit | -$10M | -$309M |
| Free Cash FlowCash after capex | -$1M | $94M |
| Gross MarginGross profit ÷ Revenue | +53.0% | +63.7% |
| Operating MarginEBIT ÷ Revenue | -8.2% | -16.6% |
| Net MarginNet income ÷ Revenue | -4.4% | -14.6% |
| FCF MarginFCF ÷ Revenue | -0.6% | +4.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +24.1% | +34.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +75.7% | -146.2% |
Valuation Metrics
CERS leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $519M | $29.6B |
| Enterprise ValueMkt cap + debt − cash | $596M | $28.8B |
| Trailing P/EPrice ÷ TTM EPS | -31.59x | -140.58x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 2.52x | 17.43x |
| Price / BookPrice ÷ Book value/share | 7.60x | 22.44x |
| Price / FCFMarket cap ÷ FCF | 60.90x | 427.23x |
Profitability & Efficiency
CERS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CERS delivers a -15.2% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-25 for NTRA. NTRA carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to CERS's 1.49x. On the Piotroski fundamental quality scale (0–9), NTRA scores 6/9 vs CERS's 5/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -15.2% | -24.7% |
| ROA (TTM)Return on assets | -4.4% | -17.0% |
| ROICReturn on invested capital | -19.7% | -33.3% |
| ROCEReturn on capital employed | -28.1% | -18.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 1.49x | 0.16x |
| Net DebtTotal debt minus cash | $77M | -$758M |
| Cash & Equiv.Liquid assets | $20M | $946M |
| Total DebtShort + long-term debt | $97M | $187M |
| Interest CoverageEBIT ÷ Interest expense | -2.63x | -69.90x |
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $22,333 today (with dividends reinvested), compared to $4,346 for CERS. Over the past 12 months, CERS leads with a +107.2% total return vs NTRA's +38.3%. The 3-year compound annual growth rate (CAGR) favors NTRA at 59.4% vs CERS's 5.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +31.5% | -6.0% |
| 1-Year ReturnPast 12 months | +107.2% | +38.3% |
| 3-Year ReturnCumulative with dividends | +17.2% | +305.1% |
| 5-Year ReturnCumulative with dividends | -56.5% | +123.3% |
| 10-Year ReturnCumulative with dividends | -53.0% | +2147.5% |
| CAGR (3Y)Annualised 3-year return | +5.4% | +59.4% |
Risk & Volatility
NTRA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NTRA is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than CERS's 2.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.13x | 1.26x |
| 52-Week HighHighest price in past year | $3.15 | $256.36 |
| 52-Week LowLowest price in past year | $1.15 | $131.81 |
| % of 52W HighCurrent price vs 52-week peak | +82.2% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 70.6 | 51.9 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 1.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CERS as "Buy" and NTRA as "Buy". Consensus price targets imply 54.4% upside for CERS (target: $4) vs 22.0% for NTRA (target: $263).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $262.50 |
| # AnalystsCovering analysts | 10 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
CERS leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). NTRA leads in 2 (Total Returns, Risk & Volatility). 1 tied.
CERS vs NTRA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CERS or NTRA a better buy right now?
For growth investors, Natera, Inc.
(NTRA) is the stronger pick with 56. 7% revenue growth year-over-year, versus 14. 3% for Cerus Corporation (CERS). Analysts rate Cerus Corporation (CERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CERS or NTRA?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +123. 3%, compared to -56. 5% for Cerus Corporation (CERS). Over 10 years, the gap is even starker: NTRA returned +21. 5% versus CERS's -53. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CERS or NTRA?
By beta (market sensitivity over 5 years), Natera, Inc.
(NTRA) is the lower-risk stock at 1. 26β versus Cerus Corporation's 2. 13β — meaning CERS is approximately 70% more volatile than NTRA relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 16% versus 149% for Cerus Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — CERS or NTRA?
By revenue growth (latest reported year), Natera, Inc.
(NTRA) is pulling ahead at 56. 7% versus 14. 3% for Cerus Corporation (CERS). On earnings-per-share growth, the picture is similar: Natera, Inc. grew EPS 59. 5% year-over-year, compared to 25. 5% for Cerus Corporation. Over a 3-year CAGR, NTRA leads at 39. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CERS or NTRA?
Cerus Corporation (CERS) is the more profitable company, earning -7.
6% net margin versus -11. 2% for Natera, Inc. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NTRA leads at -13. 1% versus -17. 6% for CERS. At the gross margin level — before operating expenses — NTRA leads at 60. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CERS or NTRA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CERS or NTRA better for a retirement portfolio?
For long-horizon retirement investors, Natera, Inc.
(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Cerus Corporation (CERS) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +21. 5%, CERS: -53. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CERS and NTRA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CERS is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.